GSK PLC Sponsored ADR Announces Quarterly Dividend of $0.44 (NYSE:GSK)

GSK PLC Sponsored ADR (NYSE:GSK) announced a quarterly dividend on Wednesday, April 29th. Shareholders of record on Friday, May 15th will be given a dividend of 0.44 per share by the pharmaceutical company on Thursday, July 9th. This represents a c) annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend is Friday, May 15th.

GSK has decreased its dividend payment by an average of 0.1%annually over the last three years. GSK has a dividend payout ratio of 38.8% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect GSK to earn $5.09 per share next year, which means the company should continue to be able to cover its $1.88 annual dividend with an expected future payout ratio of 36.9%.

GSK Stock Performance

NYSE GSK opened at $51.65 on Friday. The firm has a market capitalization of $104.81 billion, a P/E ratio of 13.42, a PEG ratio of 2.98 and a beta of 0.46. The stock has a 50-day simple moving average of $55.78 and a two-hundred day simple moving average of $51.62. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.54 and a current ratio of 0.82. GSK has a fifty-two week low of $35.45 and a fifty-two week high of $61.69.

GSK (NYSE:GSK) last announced its quarterly earnings results on Thursday, February 5th. The pharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.04. The company had revenue of $11.59 billion during the quarter, compared to the consensus estimate of $8.48 billion. GSK had a return on equity of 45.90% and a net margin of 17.82%.GSK’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.23 earnings per share. On average, equities analysts forecast that GSK will post 4.88 earnings per share for the current year.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.